RecruitingNCT05847192

Tau Networks in Psychotic Alzheimer's Disease


Sponsor

Northwell Health

Enrollment

91 participants

Start Date

Apr 13, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social cognition, working memory and executive function deficits). The investigator's previous work suggests a role of tau pathology (one of the hallmarks of AD neuropathology) in the manifestation of psychosis in AD. However, the cerebral mechanisms that underly this association remain poorly understood. The overarching aim of the study is is to investigate the mechanisms by which tau network pathology may promote the presentation of psychosis in AD.


Eligibility

Min Age: 65 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is using brain imaging to better understand how the tau protein (a hallmark of Alzheimer's disease) spreads through brain networks — and whether psychosis symptoms (like hallucinations or delusions) in Alzheimer's patients are linked to specific patterns of tau buildup. **You may be eligible if...** - You are between 65 and 85 years old - You have a confirmed diagnosis of Alzheimer's disease dementia - You have mild to moderate memory and thinking problems (as measured by a standard test) - You may or may not have psychosis symptoms - You have a family member or carer who can accompany you **You may NOT be eligible if...** - You have another type of dementia or brain disorder - You have a history of major psychiatric illness unrelated to Alzheimer's - You are unable to undergo brain imaging (MRI or PET scan) - You have metal implants or other contraindications to MRI - You are taking certain medications that could interfere with the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST[18F]-PI2620 PET scan

The PET scan will measure the regional distribution of tau aggregation in AD patients with and without psychosis compared to Cognitively Unimpaired Healthy participants with the PET radiotracer \[18F\]-PI2620.


Locations(1)

The Feinstein Institutes for Medical Research

Manhasset, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05847192


Related Trials